Pharma of the Year:
While rivals have hit setbacks, Merck's largely executed on a clinical program for Keytruda that's put the pharma on top in immuno-oncology.
Biotech of the Year
The biotech's gene therapy Luxturna, priced at $850,000 per patient, is testing a healthcare system not designed for transformative, one-time treatments.
Exec of the Year
Since taking the helm, Walmsley has launched an R&D restructure, shaken up GSK's top leadership and reset a corporate strategy that's failed to deliver industry-leading growth.
Deal of the Year
The $62 billion takeout is the largest acquisition of a foreign company in Japan's history, and would transform Takeda into the 9th largest pharma globally.
Innovation of the Year
The arrival of Onpattro and Tegsedi cap decades of progress in the field, which has once again drawn the eye of big pharma.